IP Library › Granted Patent US 10,378,040
Granted Patent B2
US 10,378,040 · App. 14/036,784 · Granted Aug 13, 2019

Mice that produce hybrid antibodies

Inventors: Andrew J. Murphy (Croton-On-Hudson, NY); George D. Yancopoulos (Yorktown Heights, NY); Margaret Karow (Santa Rosa, CA); Lynn Macdonald (Harrison, NY); Sean Stevens (Del Mar, CA); Aris N. Economides (Tarrytown, NY); David M. Valenzuela (Yorktown Heights, NY)
Assignee: Regeneron Pharmaceuticals, Inc.
C12P21/00A01K67/0275A01K67/0278C07K16/00C07K16/28C07K16/462C12N15/67C12N15/85C12N15/8509C12N15/902C12N15/907A01K2207/15A01K2217/05A01K2227/105A01K2267/01C07K2317/10C07K2317/21C07K2317/24C07K2317/51C07K2317/515C07K2317/56C12N2800/204
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,378,040
App. No.
14/036,784
Granted
Aug 13, 2019
Kind
B2
Abstract

A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.

Claims (7)

1. A transgenic mouse, whose genome comprises:

(a) unrearranged human immunoglobulin heavy chain V, D and J gene segments, wherein the unrearranged human immunoglobulin heavy chain V, D and J gene segments in situ replace endogenous mouse immunoglobulin heavy chain V, D and J gene segments, and the unrearranged human immunoglobulin heavy chain V, D and J gene segments are operably linked to an endogenous mouse heavy chain immunoglobulin constant region gene, wherein the mouse immunoglobulin heavy chain constant region gene is located at an endogenous mouse immunoglobulin heavy chain constant region locus, wherein the unrearranged human immunoglobulin heavy chain V, D and J gene segments are present in the germline of the mouse, wherein rearrangement of the human immunoglobulin heavy chain V, D and J gene segments in the mouse results in a rearranged immunoglobulin human heavy chain variable region gene linked to the mouse immunoglobulin heavy chain constant region gene; and

(b) unrearranged human immunoglobulin kappa light chain V and J gene segments, wherein the unrearranged human immunoglobulin kappa light chain V and J gene segments in situ replace endogenous mouse immunoglobulin kappa light chain V and J gene segments, and the unrearranged human immunoglobulin kappa light chain V and J gene segments are operably linked to an endogenous mouse immunoglobulin kappa light chain constant region gene, wherein the mouse immunoglobulin kappa light chain constant region gene is located at an endogenous mouse immunoglobulin kappa light chain constant region locus, wherein the unrearranged human immunoglobulin kappa light chain V and J gene segments are present in the germline of the mouse, wherein rearrangement of the human immunoglobulin kappa light chain V and J gene segments in the mouse results in a rearranged human immunoglobulin kappa light chain variable region gene linked to the mouse immunoglobulin kappa light chain constant region gene;

wherein the mouse in response to an antigen produces a hybrid antibody that comprises a human immunoglobulin heavy chain variable region encoded by the rearranged human immunoglobulin heavy chain variable region gene, a mouse immunoglobulin heavy chain constant region encoded by the mouse immunoglobulin heavy chain constant region gene, a human immunoglobulin kappa light chain variable region encoded by the rearranged human immunoglobulin kappa light chain variable region gene, and a mouse immunoglobulin kappa light chain constant region encoded by the mouse immunoglobulin kappa light chain constant region gene.

2. The mouse of claim 1 , wherein mouse V segments are present upstream of the unrearranged human immunoglobulin heavy chain V, D, and J gene segments.

3. The mouse of claim 1 , wherein the endogenous immunoglobulin enhancer Eμ remains intact upstream of the endogenous mouse immunoglobulin heavy chain constant region gene.

4. The mouse of claim 2 , wherein the endogenous immunoglobulin enhancer Eμ remains intact upstream of the endogenous mouse immunoglobulin heavy chain constant region gene.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2014
From: ECONOMIDES, ARIS N.; VALENZUELA, DAVID M.
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 032738/0571 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 11, 2014
From: MURPHY, ANDREW J.; YANCOPOULOS, GEORGE D.; KAROW, MARGARET; MACDONALD, LYNN; STEVENS, SEAN
To: REGENERON PHARMACEUTICALS INC.
Reel/Frame 032406/0956 →
Continuity (12)
Continuation 13719819 · Dec 19, 2012
Continuation 13154976 · Jun 7, 2011
Continuation 11595427 · Nov 9, 2006
Continuation 10624044 · Jul 21, 2003
Division 09784859 · Feb 16, 2001
Division 14036784
Continuation 13719842 · Dec 19, 2012
Continuation 13154976 · Jun 7, 2011
Continuation 11595427 · Nov 9, 2006
Continuation 10624044 · Jul 21, 2003
Division 09784859 · Feb 16, 2001
Related Publication 20140020125A1 · Jan 16, 2014
Cited By (1)
US 12,486,335